Patents by Inventor Archana BRAHMANDAM

Archana BRAHMANDAM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210254000
    Abstract: Provided herein are methods for producing engineered T cells that express a recombinant receptor, such as for use in cell therapy. In some aspects, the provided methods include one or more steps for incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and/or cultivating the cells under conditions that promote proliferation and/or expansion, in which one or more steps is carried out in the presence of an agent that inhibits mammalian target of rapamycin (mTOR) activity. In some aspects, cultivation is performed in the presence of an agent that inhibits mammalian target of rapamycin (mTOR) activity. In some aspects, the provided methods produce genetically engineered T cells with improved persistence and/or anti-tumor activity in vivo.
    Type: Application
    Filed: November 1, 2018
    Publication date: August 19, 2021
    Applicants: Juno Therapeutics, Inc., Celgene Corporation
    Inventors: Archana BRAHMANDAM, Lucas James THOMPSON, Deborah MORTENSEN, Ellen FILVAROFF
  • Publication number: 20180355014
    Abstract: Provided are chimeric receptors for engineering cells for adoptive therapy, including T cells, and the genetically engineered cells. In some embodiments, the chimeric receptors, such as chimeric antigen receptors (CARs) are modified in a junction region by one or more amino acid modifications such that peptide fragments of such region exhibit a lower binding affinity for a human leukocyte antigen (HLA) and/or the region exhibits reduced immunogenicity, including following administration to a subject. In some aspects, also provided are methods and compositions for engineering and producing cells expressing such chimeric receptors, compositions containing the cells, and method for their administration to subjects. In some embodiments, features of the chimeric receptors and engineered cells containing the chimeric receptors result in methods that provide for increased or improved activity, efficacy and/or persistence.
    Type: Application
    Filed: December 2, 2016
    Publication date: December 13, 2018
    Applicant: Juno Therapeutics, Inc.
    Inventors: Lucas James THOMPSON, Robert F. DUBOSE, Archana BRAHMANDAM
  • Publication number: 20180319862
    Abstract: Provided are chimeric receptors for engineering cells for adoptive therapy, including T cells, and the genetically engineered cells. In some aspects, also provided are methods and compositions for engineering and producing the cells, compositions containing the cells, and method for their administration to subjects. In some embodiments, the cells, such as T cells, contain genetically engineered antigen receptors that specifically bind to antigens, such as a chimeric antigen receptor (CAR), and which contain an intracellular signaling domain capable of inducing TRAF6-mediated signaling. In some embodiments, features of the cells and methods provide for increased or improved activity, efficacy and/or persistence.
    Type: Application
    Filed: November 4, 2016
    Publication date: November 8, 2018
    Applicant: Juno Therapeutics, Inc.
    Inventors: Lucas James THOMPSON, Valerie ODEGARD, Blythe SATHER, Archana BRAHMANDAM